Table 1.

Summary of clinical trials used in this population pharmacokinetic modeling study

Study	Dosing regimen	Indication	Number of subjects	Number of PK samples	Scheduled PK time points
SHR-1210-101	1 mg/kg, 3 mg/kg, 10 mg/kg and 200 mg. Cycle 1: 28 days; Cycle 2 and subsequent cycles: every 2 weeks	Advanced solid tumors	49	1140	Cycle 1: 30 min before and 0.1, 2, 6, 24, 48, 168, 336, 504 h after end of infusion on day 1 Cycle 2 and subsequent cycles: 30 min before and 0.1 h after end of infusion on day 1 and 15
SHR-1210-102	60 mg, 200 mg and 400 mg. Cycle 1: 28 days; Cycle 2 and subsequent cycles: every 2 weeks	Advanced melanoma	36	986	Same as the study SHR-1210-101
SHR-1210-103	60 mg, 200 mg and 400 mg. Cycle 1: 28 days; Cycle 2 and subsequent cycles: every 2 weeks	Advanced solid tumors	36	1052	Same as the study SHR-1210-101
SHR-1210-II-204	200 mg, Q2W	Relapsed or refractory classical Hodgkin lymphoma	12	120	Cycle 1: 30 min before and 0.1, 2 h after end of infusion Cycle 2, Cycle 4 and Cycle 6: 30 min before and 0.1 h after end of infusion